Roche withdraws Accutane from the US for business reasons
This article was originally published in Scrip
Executive Summary
Roche has withdrawn its severe acne treatment Accutane (isotretinoin) from the US market citing rising generic competition. The firm informed the US FDA that it would remove the product after reviewing generic competition for its product portfolio.